中国生化药物杂志
中國生化藥物雜誌
중국생화약물잡지
CHINESE JOURNAL OF BIOCHEMICAL PHARMACEUTICS
2014年
4期
33-35,39
,共4页
韩立杰%刘伟%杜娟%魏冬冬
韓立傑%劉偉%杜娟%魏鼕鼕
한립걸%류위%두연%위동동
转铁蛋白%八聚精氨酸%肿瘤靶向
轉鐵蛋白%八聚精氨痠%腫瘤靶嚮
전철단백%팔취정안산%종류파향
transferrin%R8%tumor targeting
目的:制备转铁蛋白(transferrin,TF)和八聚精氨酸(R8)共修饰脂质体(TF/R8-LP),对其理化性质进行表征,研究脂质体对肿瘤细胞的靶向性。方法采用薄膜分散法制备TF/R8-LP,研究脂质体的粒径,电位和血清稳定性。细胞摄取实验研究肝癌HepG2细胞对TF/R8-LP的摄取效率。构建裸鼠肝癌异位瘤模型,研究脂质体的体内靶向性。结果 TF/R8-LP的粒径在(108.5±12.6)nm,电位为(24.15±4.78)mV。TF/R8-LP在50%血清中具有良好的稳定性。细胞摄取实验结果显示:TF/R8-LP在4 h摄取效率是2 h的1.85倍,差异具有统计学意义(P<0.05);肝癌HepG2细胞在与脂质体共同孵育4 h后对TF/R8-LP的摄取效率分别是R8-LP、TF-LP和LP的2.4倍、2.8倍和3.9倍,差异均有统计学意义(P<0.01);近红外活体成像实验结果显示:TF/R8-LP组在肿瘤组织荧光明显强于其他组。结论转铁蛋白和八聚精氨酸共修饰脂质体具有良好的肝癌细胞亲和力,是一种潜在高效的肝癌靶向给药系统。
目的:製備轉鐵蛋白(transferrin,TF)和八聚精氨痠(R8)共脩飾脂質體(TF/R8-LP),對其理化性質進行錶徵,研究脂質體對腫瘤細胞的靶嚮性。方法採用薄膜分散法製備TF/R8-LP,研究脂質體的粒徑,電位和血清穩定性。細胞攝取實驗研究肝癌HepG2細胞對TF/R8-LP的攝取效率。構建裸鼠肝癌異位瘤模型,研究脂質體的體內靶嚮性。結果 TF/R8-LP的粒徑在(108.5±12.6)nm,電位為(24.15±4.78)mV。TF/R8-LP在50%血清中具有良好的穩定性。細胞攝取實驗結果顯示:TF/R8-LP在4 h攝取效率是2 h的1.85倍,差異具有統計學意義(P<0.05);肝癌HepG2細胞在與脂質體共同孵育4 h後對TF/R8-LP的攝取效率分彆是R8-LP、TF-LP和LP的2.4倍、2.8倍和3.9倍,差異均有統計學意義(P<0.01);近紅外活體成像實驗結果顯示:TF/R8-LP組在腫瘤組織熒光明顯彊于其他組。結論轉鐵蛋白和八聚精氨痠共脩飾脂質體具有良好的肝癌細胞親和力,是一種潛在高效的肝癌靶嚮給藥繫統。
목적:제비전철단백(transferrin,TF)화팔취정안산(R8)공수식지질체(TF/R8-LP),대기이화성질진행표정,연구지질체대종류세포적파향성。방법채용박막분산법제비TF/R8-LP,연구지질체적립경,전위화혈청은정성。세포섭취실험연구간암HepG2세포대TF/R8-LP적섭취효솔。구건라서간암이위류모형,연구지질체적체내파향성。결과 TF/R8-LP적립경재(108.5±12.6)nm,전위위(24.15±4.78)mV。TF/R8-LP재50%혈청중구유량호적은정성。세포섭취실험결과현시:TF/R8-LP재4 h섭취효솔시2 h적1.85배,차이구유통계학의의(P<0.05);간암HepG2세포재여지질체공동부육4 h후대TF/R8-LP적섭취효솔분별시R8-LP、TF-LP화LP적2.4배、2.8배화3.9배,차이균유통계학의의(P<0.01);근홍외활체성상실험결과현시:TF/R8-LP조재종류조직형광명현강우기타조。결론전철단백화팔취정안산공수식지질체구유량호적간암세포친화력,시일충잠재고효적간암파향급약계통。
Objective To prepare transferring and R8 co-modified liposome (TF/R8-LP)for forhepatoma targeting.Methods The co-modified liposome were prepared by film-ultrasonic method.The appearance,particle size,Zeta potential were evaluated.The cellular uptake by HepG2 cell in vitro was used to evaluate the targeting efficiency and in vivo imaging were used to evaluate the targeting efficiency. Results The particle diameter of the co-modified liposome was(108.5 ±12.6)nm and the Zeta potential was(24.15 ±4.78)mV.The liposome kept stable in 50% FBS at 24 h.The result demonstrated that the co-modified liposome uptaken by HepG2 were 2.4,2.6 times higher than that of R8-LP and TF-LP,respectively(P<0.05).The evaluation of tumor spheroid penetration and in vivo imaging results showed the co-modified liposome had the strongest fluorescence intensity. Conclusion The co-modified liposome might serve as a promising hepatoma delivery system of antitumor drugs.